Now showing items 1-20 of 54

    • A case-control study of risk of leukaemia in relation to mobile phone use. 

      Cooke, R; Laing, S; Swerdlow, AJ (2010-11)
      Background Mobile phone use is now ubiquitous, and scientific reviews have recommended research into its relation to leukaemia risk, but no large studies have been conducted.Methods In a case-control study in South East ...
    • Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors. 

      Quigley, D; Alumkal, JJ; Wyatt, AW; Kothari, V; Foye, A; Lloyd, P; Aggarwal, R; Kim, W; Lu, E; Schwartzman, J; Beja, K; Annala, M; Das, R; Diolaiti, M; Pritchard, C; Thomas, G; Tomlins, S; Knudsen, K; Lord, CJ; Ryan, C; Youngren, J; Beer, TM; Ashworth, A; Small, EJ; Feng, FY (2017-09)
      Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as <i>BRCA2</i> HRR defects confer synthetic lethality to PARP inhibitors ...
    • Association analyses identify 31 new risk loci for colorectal cancer susceptibility. 

      Law, PJ; Timofeeva, M; Fernandez-Rozadilla, C; Broderick, P; Studd, J; Fernandez-Tajes, J; Farrington, S; Svinti, V; Palles, C; Orlando, G; Sud, A; Holroyd, A; Penegar, S; Theodoratou, E; Vaughan-Shaw, P; Campbell, H; Zgaga, L; Hayward, C; Campbell, A; Harris, S; Deary, IJ; Starr, J; Gatcombe, L; Pinna, M; Briggs, S; Martin, L; Jaeger, E; Sharma-Oates, A; East, J; Leedham, S; Arnold, R; Johnstone, E; Wang, H; Kerr, D; Kerr, R; Maughan, T; Kaplan, R; Al-Tassan, N; Palin, K; Hänninen, UA; Cajuso, T; Tanskanen, T; Kondelin, J; Kaasinen, E; Sarin, A-P; Eriksson, JG; Rissanen, H; Knekt, P; Pukkala, E; Jousilahti, P; Salomaa, V; Ripatti, S; Palotie, A; Renkonen-Sinisalo, L; Lepistö, A; Böhm, J; Mecklin, J-P; Buchanan, DD; Win, A-K; Hopper, J; Jenkins, ME; Lindor, NM; Newcomb, PA; Gallinger, S; Duggan, D; Casey, G; Hoffmann, P; Nöthen, MM; Jöckel, K-H; Easton, DF; Pharoah, PDP; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; PRACTICAL consortium; Harkin, A; Allan, K; McQueen, J; Paul, J; Iveson, T; Saunders, M; Butterbach, K; Chang-Claude, J; Hoffmeister, M; Brenner, H; Kirac, I; Matošević, P; Hofer, P; Brezina, S; Gsur, A; Cheadle, JP; Aaltonen, LA; Tomlinson, I; Houlston, RS; Dunlop, MG (2019-05-14)
      Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that ...
    • Brain and Salivary Gland Tumors and Mobile Phone Use: Evaluating the Evidence from Various Epidemiological Study Designs. 

      Röösli, M; Lagorio, S; Schoemaker, MJ; Schüz, J; Feychting, M (2019-04)
      Mobile phones (MPs) are the most relevant source of radiofrequency electromagnetic field (RF-EMF) exposure to the brain and the salivary gland. Whether this exposure implies a cancer risk has been addressed in several ...
    • Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells. 

      Wong, P-P; Muñoz-Félix, JM; Hijazi, M; Kim, H; Robinson, SD; De Luxán-Delgado, B; Rodríguez-Hernández, I; Maiques, O; Meng, Y-M; Meng, Q; Bodrug, N; Dukinfield, MS; Reynolds, LE; Elia, G; Clear, A; Harwood, C; Wang, Y; Campbell, JJ; Singh, R; Zhang, P; Schall, TJ; Matchett, KP; Henderson, NC; Szlosarek, PW; Dreger, SA; Smith, S; Jones, JL; Gribben, JG; Cutillas, PR; Meier, P; Sanz-Moreno, V; Hodivala-Dilke, KM (2020-06)
      Enhanced blood vessel (BV) formation is thought to drive tumor growth through elevated nutrient delivery. However, this observation has overlooked potential roles for mural cells in directly affecting tumor growth independent ...
    • Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study. 

      Swerdlow, AJ; Cooke, R; Beckers, D; Borgström, B; Butler, G; Carel, J-C; Cianfarani, S; Clayton, P; Coste, J; Deodati, A; Ecosse, E; Gausche, R; Giacomozzi, C; Hokken-Koelega, ACS; Khan, AJ; Kiess, W; Kuehni, CE; Mullis, P-E; Pfaffle, R; Sävendahl, L; Sommer, G; Thomas, M; Tidblad, A; Tollerfield, S; Van Eycken, L; Zandwijken, GRJ (2017-05)
      Context Growth hormone (GH) is prescribed for an increasing range of indications, but there has been concern that it might raise cancer risk. Published data are limited.Objective To examine cancer risks in relation to GH ...
    • CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer. 

      Lim, JSJ; Turner, NC; Yap, TA (2016-07)
      Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast ...
    • Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. 

      Goodall, J; Mateo, J; Yuan, W; Mossop, H; Porta, N; Miranda, S; Perez-Lopez, R; Dolling, D; Robinson, DR; Sandhu, S; Fowler, G; Ebbs, B; Flohr, P; Seed, G; Rodrigues, DN; Boysen, G; Bertan, C; Atkin, M; Clarke, M; Crespo, M; Figueiredo, I; Riisnaes, R; Sumanasuriya, S; Rescigno, P; Zafeiriou, Z; Sharp, A; Tunariu, N; Bianchini, D; Gillman, A; Lord, CJ; Hall, E; Chinnaiyan, AM; Carreira, S; de Bono, JS; TOPARP-A investigators (2017-09)
      Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity ...
    • Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. 

      Allin, DM; Shaikh, R; Carter, P; Thway, K; Sharabiani, MTA; Gonzales-de-Castro, D; O'Leary, B; Garcia-Murillas, I; Bhide, S; Hubank, M; Harrington, K; Kim, D; Newbold, K (2018-11)
      Background Conventional biomarkers in thyroid cancer are not disease specific and fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA (ctDNA) has been shown to be a useful biomarker in ...
    • Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts. 

      McCullough, ML; Zoltick, ES; Weinstein, SJ; Fedirko, V; Wang, M; Cook, NR; Eliassen, AH; Zeleniuch-Jacquotte, A; Agnoli, C; Albanes, D; Barnett, MJ; Buring, JE; Campbell, PT; Clendenen, TV; Freedman, ND; Gapstur, SM; Giovannucci, EL; Goodman, GG; Haiman, CA; Ho, GYF; Horst, RL; Hou, T; Huang, W-Y; Jenab, M; Jones, ME; Joshu, CE; Krogh, V; Lee, I-M; Lee, JE; Männistö, S; Le Marchand, L; Mondul, AM; Neuhouser, ML; Platz, EA; Purdue, MP; Riboli, E; Robsahm, TE; Rohan, TE; Sasazuki, S; Schoemaker, MJ; Sieri, S; Stampfer, MJ; Swerdlow, AJ; Thomson, CA; Tretli, S; Tsugane, S; Ursin, G; Visvanathan, K; White, KK; Wu, K; Yaun, S-S; Zhang, X; Willett, WC; Gail, MH; Ziegler, RG; Smith-Warner, SA (2019-02)
      Background Experimental and epidemiological studies suggest a protective role for vitamin D in colorectal carcinogenesis, but evidence is inconclusive. Circulating 25-hydroxyvitamin D (25(OH)D) concentrations that minimize ...
    • Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme. 

      Davidson, M; Aronson, LI; Howard-Reeves, J; Bryant, H; Cutts, RJ; Hulkki-Wilson, S; Kouvelakis, K; Kalaitzaki, E; Watkins, D; Starling, N; Rao, S; Cardenosa, ML; Begum, R; Rana, I; Lazaro-Alcausi, R; Terlizzo, M; Wotherspoon, A; Brown, G; Swansbury, J; Lord, CJ; Cunningham, D; Chau, I; Chong, IY (2019-11)
      Introduction The MYC proto-oncogene is among the most commonly dysregulated genes in human cancers. We report screening data from the iMYC trial, an ongoing phase II study assessing ibrutinib monotherapy in advanced ...
    • Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. 

      Sud, A; Jones, ME; Broggio, J; Loveday, C; Torr, B; Garrett, A; Nicol, DL; Jhanji, S; Boyce, SA; Gronthoud, F; Ward, P; Handy, JM; Yousaf, N; Larkin, J; Suh, Y-E; Scott, S; Pharoah, PDP; Swanton, C; Abbosh, C; Williams, M; Lyratzopoulos, G; Houlston, R; Turnbull, C (2020-08)
      Background Cancer diagnostics and surgery have been disrupted by the response of health care services to the coronavirus disease 2019 (COVID-19) pandemic. Progression of cancers during delay will impact on patients' long-term ...
    • Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 

      Fehringer, G; Kraft, P; Pharoah, PD; Eeles, RA; Chatterjee, N; Schumacher, FR; Schildkraut, JM; Lindström, S; Brennan, P; Bickeböller, H; Houlston, RS; Landi, MT; Caporaso, N; Risch, A; Amin Al Olama, A; Berndt, SI; Giovannucci, EL; Grönberg, H; Kote-Jarai, Z; Ma, J; Muir, K; Stampfer, MJ; Stevens, VL; Wiklund, F; Willett, WC; Goode, EL; Permuth, JB; Risch, HA; Reid, BM; Bezieau, S; Brenner, H; Chan, AT; Chang-Claude, J; Hudson, TJ; Kocarnik, JK; Newcomb, PA; Schoen, RE; Slattery, ML; White, E; Adank, MA; Ahsan, H; Aittomäki, K; Baglietto, L; Blomquist, C; Canzian, F; Czene, K; Dos-Santos-Silva, I; Eliassen, AH; Figueroa, JD; Flesch-Janys, D; Fletcher, O; Garcia-Closas, M; Gaudet, MM; Johnson, N; Hall, P; Hazra, A; Hein, R; Hofman, A; Hopper, JL; Irwanto, A; Johansson, M; Kaaks, R; Kibriya, MG; Lichtner, P; Liu, J; Lund, E; Makalic, E; Meindl, A; Müller-Myhsok, B; Muranen, TA; Nevanlinna, H; Peeters, PH; Peto, J; Prentice, RL; Rahman, N; Sanchez, MJ; Schmidt, DF; Schmutzler, RK; Southey, MC; Tamimi, R; Travis, RC; Turnbull, C; Uitterlinden, AG; Wang, Z; Whittemore, AS; Yang, XR; Zheng, W; Buchanan, DD; Casey, G; Conti, DV; Edlund, CK; Gallinger, S; Haile, RW; Jenkins, M; Le Marchand, L; Li, L; Lindor, NM; Schmit, SL; Thibodeau, SN; Woods, MO; Rafnar, T; Gudmundsson, J; Stacey, SN; Stefansson, K; Sulem, P; Chen, YA; Tyrer, JP; Christiani, DC; Wei, Y; Shen, H; Hu, Z; Shu, X-O; Shiraishi, K; Takahashi, A; Bossé, Y; Obeidat, M; Nickle, D; Timens, W; Freedman, ML; Li, Q; Seminara, D; Chanock, SJ; Gong, J; Peters, U; Gruber, SB; Amos, CI; Sellers, TA; Easton, DF; Hunter, DJ; Haiman, CA; Henderson, BE; Hung, RJ; Ovarian Cancer Association Consortium (OCAC); PRACTICAL Consortium; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); Colorectal Transdisciplinary (CORECT) Study; African American Breast Cancer Consortium (AABC) and African Ancestry Prostate Cancer Consortium (AAPC) (2016-09)
      Identifying genetic variants with pleiotropic associations can uncover common pathways influencing multiple cancers. We took a two-stage approach to conduct genome-wide association studies for lung, ovary, breast, prostate, ...
    • Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer. 

      Dodson, A; Okonji, D; Assersohn, L; Rigg, A; Sheri, A; Turner, N; Smith, I; Parton, M; Dowsett, M (2018-02)
      Purpose Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chemotherapy use in patients with primary oestrogen receptor-positive (ER+) breast cancer, produces a recurrence score (RS) ...
    • DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. 

      Mateo, J; Carreira, S; Sandhu, S; Miranda, S; Mossop, H; Perez-Lopez, R; Nava Rodrigues, D; Robinson, D; Omlin, A; Tunariu, N; Boysen, G; Porta, N; Flohr, P; Gillman, A; Figueiredo, I; Paulding, C; Seed, G; Jain, S; Ralph, C; Protheroe, A; Hussain, S; Jones, R; Elliott, T; McGovern, U; Bianchini, D; Goodall, J; Zafeiriou, Z; Williamson, CT; Ferraldeschi, R; Riisnaes, R; Ebbs, B; Fowler, G; Roda, D; Yuan, W; Wu, YM; Cao, X; Brough, R; Pemberton, H; A'Hern, R; Swain, A; Kunju, LP; Eeles, R; Attard, G; Lord, CJ; Ashworth, A; Rubin, MA; Knudsen, KE; Feng, FY; Chinnaiyan, AM; Hall, E; de Bono, JS
      Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to ...
    • Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. 

      Sud, A; Torr, B; Jones, ME; Broggio, J; Scott, S; Loveday, C; Garrett, A; Gronthoud, F; Nicol, DL; Jhanji, S; Boyce, SA; Williams, M; Riboli, E; Muller, DC; Kipps, E; Larkin, J; Navani, N; Swanton, C; Lyratzopoulos, G; McFerran, E; Lawler, M; Houlston, R; Turnbull, C (2020-08)
      Background During the COVID-19 lockdown, referrals via the 2-week-wait urgent pathway for suspected cancer in England, UK, are reported to have decreased by up to 84%. We aimed to examine the impact of different scenarios ...
    • Exposure to loud noise and risk of vestibular schwannoma: results from the INTERPHONE international case‒control study. 

      Deltour, I; Schlehofer, B; Massardier-Pilonchéry, A; Schlaefer, K; Armstrong, B; Giles, GG; Siemiatycki, J; Parent, M-E; Krewski, D; McBride, M; Johansen, C; Auvinen, A; Salminen, T; Hours, M; Montestrucq, L; Blettner, M; Berg-Beckhoff, G; Sadetzki, S; Chetrit, A; Lagorio, S; Iavarone, I; Yamaguchi, N; Takebayashi, T; Woodward, A; Cook, A; Tynes, T; Klaeboe, L; Maria Feychting, MF; Lönn, S; Fleming, S; Swerdlow, AJ; Schoemaker, MJ; Moissonnier, M; Kesminiene, A; Cardis, E; Schüz, J; INTERPHONE Study Group (2019-03)
      Objective Studies of loud noise exposure and vestibular schwannomas (VS) have shown conflicting results. The population-based INTERPHONE case‒control study was conducted in 13 countries during 2000-2004. In this paper, we ...
    • Familial gigantism caused by an NSD1 mutation. 

      van Haelst, MM; Hoogeboom, JJM; Baujat, G; Brüggenwirth, HT; Van de Laar, I; Coleman, K; Rahman, N; Niermeijer, MF; Drop, SLS; Scambler, PJ (2005-11)
      A three-generation family with autosomal dominant segregation of a novel NSD1 mutation (6605G --> A, resulting in Cys2202Tyr) is reported. Haploinsufficiency of NSD1 has been identified as the major cause of Sotos syndrome. ...
    • Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. 

      Khan, K; Rata, M; Cunningham, D; Koh, D-M; Tunariu, N; Hahne, JC; Vlachogiannis, G; Hedayat, S; Marchetti, S; Lampis, A; Damavandi, MD; Lote, H; Rana, I; Williams, A; Eccles, SA; Fontana, E; Collins, D; Eltahir, Z; Rao, S; Watkins, D; Starling, N; Thomas, J; Kalaitzaki, E; Fotiadis, N; Begum, R; Bali, M; Rugge, M; Temple, E; Fassan, M; Chau, I; Braconi, C; Valeri, N (2018-08)
      Objective Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better ...
    • GABA immunoreactivity in the human cerebellar cortex: a light and electron microscopical study. 

      Benagiano, V; Roncali, L; Virgintino, D; Flace, P; Errede, M; Rizzi, A; Girolamo, F; Robertson, D; Bormann, J; Ambrosi, G (2001-09)
      The distribution of gamma-aminobutyric acid (GABA) in surgical samples of human cerebellar cortex was studied by light and electron microscope immunocytochemistry using a polyclonal antibody generated in rabbit against ...